[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin,2021,71(3):209-249.
[2] Beaufrere A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: An update. J Hepatol,2021,74(5):1212-1224.
[3] Valery PC, Laversanne M, Clark PJ, et al. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology,2018,67(2):600-611.
[4] Zhang H, Yang T, Wu M, et al. Intrahepatic cholangiocarcinoma: Epidemiology, risk factors,diagnosis and surgical management. Cancer Lett,2016,379(2):198-205.
[5] Florio AA, Ferlay J, Znaor A, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer,2020,126(11):2666-2678.
[6] Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Nat Rev Dis Primers,2018,4:18036.
[7] Manns MP, Maasoumy B. Breakthroughs in hepatitis C research: from discovery to cure. Nat Rev Gastroenterol Hepatol,2022,19(8):533-550.
[8] Li X, Ramadori P, Pfister D, et al. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer,2021,21(9):541-557.
[9] Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology,2011, 54(1):173-184.
[10] Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int,2019,39 Suppl 1:19-31.
[11] Dinh TA, Utria AF, Barry KC, et al. A framework for fibrolamellar carcinoma research and clinical trials. Nat Rev Gastroenterol Hepatol,2022,19(5):328-342.
[12] Calderaro J, Couchy G, Imbeaud S, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol,2017,67(4):727-738.
[13] Kendall T, Verheij J, Gaudio E, et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int,2019,39 Suppl 1:7-18.
[14] Paradis V, Zucman-Rossi J . Pathogenesis of primary liver carcinomas. J Hepatol,2023,78(2):448-449.
[15] Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet,2018,391(10127):1301-1314.
[16] Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers,2021,7(1):6.
[17] Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol,2022, 19(3):151-172.
[18] Parikh ND, Pillai A. Recent Advances in Hepatocellular Carcinoma Treatment. Clin Gastroenterol Hepatol,2021,19(10):2020-2024.
[19] Mazzaferro V, Gorgen A, Roayaie S, et al. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol,2020,72(2):364-377.
[20] Oh DY, Lee KH, Lee DW, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol, 2022,7(6):522-532.
[21] Kelley RK, Bridgewater J, Gores GJ, et al. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol,2020,72(2):353-363. |
